794 related articles for article (PubMed ID: 26062943)
21. Progress in the treatment of elderly/unfit chronic lymphocytic leukemia patients: results of the German CLL-11 trial.
Molica S
Expert Rev Anticancer Ther; 2015 Jan; 15(1):9-15. PubMed ID: 25479582
[TBL] [Abstract][Full Text] [Related]
22. A canadian perspective on the first-line treatment of chronic lymphocytic leukemia.
Owen C; Bence-Bruckler I; Chamakhi I; Toze C; Assaily W; Christofides A; Robinson S
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):303-13. PubMed ID: 25937158
[TBL] [Abstract][Full Text] [Related]
23. Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia.
Cervantes-Gomez F; Lamothe B; Woyach JA; Wierda WG; Keating MJ; Balakrishnan K; Gandhi V
Clin Cancer Res; 2015 Aug; 21(16):3705-15. PubMed ID: 25829398
[TBL] [Abstract][Full Text] [Related]
24. Role of obinutuzumab in the treatment of chronic lymphocytic leukemia.
Jean GW; Comeau JM
Am J Health Syst Pharm; 2015 Jun; 72(11):933-42. PubMed ID: 25987688
[TBL] [Abstract][Full Text] [Related]
25. Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy.
Da Roit F; Engelberts PJ; Taylor RP; Breij EC; Gritti G; Rambaldi A; Introna M; Parren PW; Beurskens FJ; Golay J
Haematologica; 2015 Jan; 100(1):77-86. PubMed ID: 25344523
[TBL] [Abstract][Full Text] [Related]
26. Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia.
Lampson BL; Kim HT; Davids MS; Abramson JS; Freedman AS; Jacobson CA; Armand PA; Joyce RM; Arnason JE; Rassenti LZ; Kipps TJ; Fein J; Fernandes SM; Hanna JR; Fisher DC; Brown JR
Blood Adv; 2019 Apr; 3(7):1167-1174. PubMed ID: 30967392
[TBL] [Abstract][Full Text] [Related]
27. Obinutuzumab for the treatment of chronic lymphocytic leukemia.
Rogers KA; Jones JA
Drugs Today (Barc); 2014 Jun; 50(6):407-19. PubMed ID: 24983589
[TBL] [Abstract][Full Text] [Related]
28. Obinutuzumab treatment in the elderly patient with chronic lymphocytic leukemia.
Seiter K; Mamorska-Dyga A
Clin Interv Aging; 2015; 10():951-61. PubMed ID: 26109852
[TBL] [Abstract][Full Text] [Related]
29. Targeted therapies for CLL: Practical issues with the changing treatment paradigm.
Jain N; O'Brien S
Blood Rev; 2016 May; 30(3):233-44. PubMed ID: 26776345
[TBL] [Abstract][Full Text] [Related]
30. Targeting of B-cell receptor signalling in B-cell malignancies.
Jerkeman M; Hallek M; Dreyling M; Thieblemont C; Kimby E; Staudt L
J Intern Med; 2017 Nov; 282(5):415-428. PubMed ID: 28295729
[TBL] [Abstract][Full Text] [Related]
31. Bruton's tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL).
Thompson PA; Burger JA
Expert Opin Investig Drugs; 2018 Jan; 27(1):31-42. PubMed ID: 29125406
[TBL] [Abstract][Full Text] [Related]
32. Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment.
Hallek M
Am J Hematol; 2015 May; 90(5):446-60. PubMed ID: 25908509
[TBL] [Abstract][Full Text] [Related]
33. Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study.
Jaglowski SM; Jones JA; Nagar V; Flynn JM; Andritsos LA; Maddocks KJ; Woyach JA; Blum KA; Grever MR; Smucker K; Ruppert AS; Heerema NA; Lozanski G; Stefanos M; Munneke B; West JS; Neuenburg JK; James DF; Hall N; Johnson AJ; Byrd JC
Blood; 2015 Aug; 126(7):842-50. PubMed ID: 26116658
[TBL] [Abstract][Full Text] [Related]
34. Ibrutinib: a novel Bruton's tyrosine kinase inhibitor with outstanding responses in patients with chronic lymphocytic leukemia.
Barrientos J; Rai K
Leuk Lymphoma; 2013 Aug; 54(8):1817-20. PubMed ID: 23617325
[TBL] [Abstract][Full Text] [Related]
35. Antibody therapy alone and in combination with targeted drugs in chronic lymphocytic leukemia.
Robak T; Blonski JZ; Robak P
Semin Oncol; 2016 Apr; 43(2):280-90. PubMed ID: 27040707
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic Approach to Patients with Chronic Lymphocytic Leukemia and Significant Comorbid Conditions.
Smolej L
Curr Cancer Drug Targets; 2016; 16(8):710-720. PubMed ID: 27055578
[TBL] [Abstract][Full Text] [Related]
37. Managing Patients With TP53-Deficient Chronic Lymphocytic Leukemia.
Edelmann J; Gribben JG
J Oncol Pract; 2017 Jun; 13(6):371-377. PubMed ID: 28605616
[TBL] [Abstract][Full Text] [Related]
38. Current Treatment of Chronic Lymphocytic Leukemia.
Jamroziak K; Puła B; Walewski J
Curr Treat Options Oncol; 2017 Jan; 18(1):5. PubMed ID: 28185174
[TBL] [Abstract][Full Text] [Related]
39. Treating chronic lymphocytic leukemia with obinutuzumab: safety and efficacy considerations.
Reda G; Orofino N; Cassin R; Sciumè M; Fattizzo B; Cortelezzi A
Expert Opin Drug Saf; 2016 Jun; 15(6):865-73. PubMed ID: 26967902
[TBL] [Abstract][Full Text] [Related]
40. Treatment approach for elderly and unfit patients with chronic lymphocytic leukemia.
Innocenti I; Autore F; Pasquale R; Morelli F; Efremov DG; Laurenti L
Expert Rev Hematol; 2017 Dec; 10(12):1069-1076. PubMed ID: 29082795
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
